Delivery of biologics to the retinal pigment epithelium by Subrizi, Astrid
Centre for Drug Research 
Division of Pharmaceutical Biosciences 
Faculty of Pharmacy 
University of Helsinki 
Finland 
 
 
 
 
 
 
 
 
DELIVERY OF BIOLOGICS 
TO THE RETINAL PIGMENT EPITHELIUM 
 
 
 
 
Astrid Subrizi 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented, with the permission of the Faculty of Pharmacy of  
the University of Helsinki, for public examination in lecture room 5 (A106),  
Latokartanonkaari 7 (B building), Viikki campus, on 22 August 2014, at 1 pm. 
 
Helsinki 2014 
Supervisor: Arto Urtti, professor 
  Centre for Drug Research 
  Division of Pharmaceutical Biosciences 
  Faculty of Pharmacy 
  University of Helsinki 
  Finland 
 
 
Reviewers: Juha Holopainen, docent 
  Helsinki Eye Lab 
  Department of Ophthalmology 
  Helsinki University Central Hospital 
  Finland 
 
  Stefaan de Smedt, professor 
Laboratory of General Biochemistry and  
Physical Pharmacy 
  Faculty of Pharmaceutical Sciences 
  Ghent University 
  Belgium 
 
 
Opponent: Jørgen Kjems, professor 
  Interdisciplinary Nanoscience Center (iNANO) 
  and Department of Molecular Biology and Genetics 
  Aarhus University 
  Denmark 
 
 
 
 
 
 
 
 
 
 
 
© Astrid Subrizi 2014 
ISBN: 978-951-51-0054-2 (print) 978-951-51-0055-9 (online) 
ISSN: 1799-7372 
 
 
Hansaprint 
Helsinki 2014 
 3 
ABSTRACT 
Biologics are increasingly used in the treatment of ocular diseases such as 
age-related macular degeneration (AMD) that cannot be controlled with 
conventional small molecule drugs. AMD is a multifactorial eye disease that 
carries significant risk of morbidity and vision loss. In Finland and other 
western countries, AMD affects one in three people older than 75 years, and 
until the early 2000s no effective treatment was available for these patients. 
The marketing approval of anti-VEGF antibodies was a major breakthrough 
in the management of AMD; indeed these biologics effectively halt choroidal 
neovascularization and therefore prevent further vision loss in roughly half of 
the patients with wet AMD. Antibody therapy has been the most successful 
approach so far, however, other biological therapies such as gene therapy, 
cell therapy and other therapeutic proteins, may prove beneficial in the 
treatment of AMD and other vision threatening disorders. This thesis deals 
with the delivery of biologics, including DNA, cells, proteins and peptides, to 
the retinal pigment epithelium (RPE), which plays a central role in the 
development of AMD. Briefly, the main topics and results of this work are 
presented. 
New non-viral gene delivery candidates are usually screened for 
transfection efficiency and toxicity by reading out transgene expression levels 
relative to a reference formulation after in vitro transfection. The screening 
protocols, however, can be very different among laboratories, so that 
comparison of results is often difficult, if not impossible (van Gaal et al., 
2011). Our aim was to develop a standardized protocol optimized for the 
transfection of retinal pigment epithelial cells in vitro. The developed 
screening protocol provides a relatively simple and reproducible procedure 
for the pre-selection of potential candidate reagents as non-viral gene 
delivery systems targeted to the retinal pigment epithelium. 
The ocular delivery of biologics remains a challenging task due to the 
barriers of the eye. Short cationic peptides, also known as cell-penetrating 
peptides (CPPs), have been successfully used as tools to introduce various 
biologics into cells due to their ability to translocate across the plasma 
membrane and deliver their cargoes intracellularly. In our work, we have 
explored the functionality of Tat peptide, one of the most widely studied 
CPPs. Our results indicate that it is not the sequence of Tat per se that 
dictates cell uptake, but the cationic charge of the peptide. Moreover no 
direct penetration was observed; instead all the peptides were endocytosed 
and, as it is often the case in non-viral gene delivery, ended their journey 
inside lysosomes. For this reason, we think that the use of Tat peptide for the 
delivery of biologics to the cytoplasm or nucleus of cells will probably not be 
very successful. 
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Ocular stem cell therapy holds promise for the reconstruction of the 
degenerated RPE monolayer in AMD patients; in addition, engineered 
human RPE constructs may also provide a unique platform for drug 
discovery and toxicology. We have grown a functional RPE tissue in vitro by 
using human embryonic stem cells as cell source and the synthetic polymer 
polyimide as supporting scaffold for the growth and maturation of the cells. 
The epithelia acquired RPE-like properties, including characteristic RPE 
phenotype, expression of RPE markers, barrier and phagocytic function. 
The degeneration of RPE cells in dry AMD is caused by the aggregation of 
proteins inside RPE cells, and is currently untreatable. We have investigated 
the cytoprotective properties of heat shock protein 70 kDa (Hsp70) against 
oxidative damage and the feasibility of rhHsp70 protein therapy as a 
potential therapeutic approach for dry AMD. This work provides a novel 
therapeutic option for the treatment of RPE degeneration in AMD. 
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1 INTRODUCTION 
Biologics are pharmaceutical products manufactured from living organisms, 
such as a microorganism, or plant or animal cells, by genetic engineering. 
They are characterized by their very large size, which is often 200 to 1000 
times the size of a small molecule drug, and by their high complexity. 
Moreover due to their size and sensitivity, biologics are almost always 
administered parenterally rather than orally like most small molecule drugs. 
The term biologics is often equated with therapeutic proteins synthesised in 
engineered systems. More recently, however, nucleic acids used in gene 
therapy and antisense technology, and cells employed in cell therapy with the 
aim to restore, maintain, or improve tissue function, gained in importance 
and they too are generally included in the definition. The first biologic to gain 
marketing approval was humulin, a recombinant human insulin developed 
and marketed by Genentech and Eli Lilly, initially approved in the United 
States in 1982 (Johnson, 1983). In the last 15 years, the pharmaceutical 
industry has undergone a “biologics boom”; by 2010 some 200 biologics had 
gained marketing approval (Walsh, 2010), commanding an estimated global 
market of about $ 115 billion (including vaccines). Millions of patients 
worldwide benefit from biologic drugs, which are employed in the treatment 
of a variety of cancers, infectious diseases, inflammatory diseases, 
autoimmune disorders, cardiovascular diseases, blood disorders, and 
diabetes. 
Age-related macular degeneration (AMD) is a vision threatening disorder 
of the posterior eye that affects millions of elderly patients worldwide. 
Although the disease rarely results in complete blindness and peripheral 
vision may remain unaltered, central vision is gradually blurred, severely 
affecting ordinary daily activities (de Jong, 2006). AMD is a disease with 
limited treatability; however, with the advent of antiangiogenic therapy with 
biologics, in about half of the patients suffering from neovascular AMD, the 
progression of the disease can be halted (Rosenfeld et al., 2006). Early 
detection is the key to a successful therapy, because anti-VEGF treatment 
may be able to prevent the growth of new blood vessels, but it cannot restore 
vision in an eye with scarring. Nevertheless with the therapy advances of the 
past 10 years, millions of patients in the early stage of wet AMD, whose 
retinal architecture is not yet compromised, were able to preserve ocular 
health, quality of vision, and independence. In order to achieve retinal 
targeting and an effective therapeutic concentration, biologics need to be 
administered by direct intravitreal injection. Monthly intravitreal injections 
of anti-VEGF antibodies/antibody fragments are the standard care for wet 
AMD patients, however this administration route, in addition to being 
uncomfortable for the patient, may also cause several adverse effects, 
including development of endophthalmitis, rise in intraocular pressure, 
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cataract formation, and increased risk of retinal detachment (Falavarjani and 
Nguyen, 2013). Hence there is an unmet medical need for new technologies 
that can provide controlled, scalable and sustained release of biologics, 
through non-invasive or minimally invasive routes to the back of the eye. 
This thesis deals with the delivery of biologics, including DNA, cells, proteins 
and peptides, to the retinal pigment epithelium, which plays a central role in 
the development of AMD. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 THE RETINAL PIGMENT EPITHELIUM IN HEALTH 
AND DISEASE 
2.1.1 THE RETINAL PIGMENT EPITHELIUM 
Vision is the ability to detect, recognize and discriminate objects in space. 
Our visual system is a highly complex arrangement for analysing information 
coming from a wide array of signals, all of which are captured by the retinal 
sensory receptors (Forrester et al., 2008): the photoreceptors. The 
photoreceptors detect light signals and convert them first to biochemical 
signals and then to electric stimuli, which are transmitted via several other 
neurons of the retina to the brain. The photoreceptors are the light sensitive 
cells in the retina, and yet even the simplest light detecting organs are 
composed also of a second cell type, the pigmented cell. Both cell types 
appear together in every eye of the animal kingdom from insects to higher 
vertebrates (Lamb et al., 2007, Kolb et al., 2014), and their interaction is 
essential for visual function. The retinal pigment epithelium (RPE) is derived 
from the same neural tissue that forms the neurosensory retina, although 
while the retina differentiates into several layers of neurons, the RPE 
remains a monolayer with characteristics of a secretory epithelium (table 1) 
(Marmor and Wolfensberger, 1998). The RPE is located in the back of the 
eye, its apical side facing the photoreceptors of the neural retina and its 
basolateral surface resting on the Bruch’s membrane, a pentalaminar, 1-4 µm 
thick structure overlaying the fenestrated choroidal capillaries of the eye 
(figure 1). 
 
Figure 1 Sagittal section of the human eye and detail of the retinal pigment epithelium. 
The RPE is sandwiched between the retina and the choroid in the posterior part of 
the eye. 
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The RPE is a cuboidal (hexagonal from above), post-mitotic, single sheet of 
pigmented cells joined apically by tight junctions which block the free 
passage of water and ions. This junctional barrier forms the outer blood-
retinal barrier that plays a crucial role in maintaining the viability and 
function of the neural retina. The RPE exerts several essential supportive 
functions of homeostasis in the neural retina (see table 1) hence, it is not 
surprising that RPE impairment plays a central role in the pathogenesis of 
several degenerative retinal disorders that lead to irreversible vision loss. 
Table 1. Physiologic functions of the RPE 
a) Light absorption 
Melanosomes absorb scattered light and improve the quality of the optical system 
Protection from  photo-oxidative damage (antioxidants) 
b) Blood-retinal barrier 
Epithelial transport of nutrients and ions 
Water and metabolic end products removal from the subretinal space 
Immune privilege 
c) Visual cycle 
Isomerization of all-trans retinal to 11-cis retinal 
Storage of 11-cis retinal 
d) Secretion of growth factors 
Essential for maintenance of the retina and choriocapillaris, e.g. fibroblast growth factors 
(FGFs), transforming growth factor-β (TGF-β), insulin-like growth factor-I (IGF-I), ciliary 
neurotrophic factor (CNTF), platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), lens epithelium-derived growth factor (LEDGF), members of the 
interleukin family, and pigment epithelium-derived factor (PEDF) (Strauss, 2005) 
e) Phagocytosis of photoreceptor outer segments 
Diurnally regulated process that is essential for the renewal of photo-oxidized photoreceptor 
outer segment tips 
 
2.1.2 AGE-RELATED MACULAR DEGENERATION 
The RPE is involved in a variety of congenital, inherited, and metabolic 
disorders, although few have been defined in terms of specific cellular 
dysfunction at the level of the RPE (Marmor and Wolfensberger, 1998). 
Degeneration of RPE cells and disruption of the RPE-photoreceptor interface 
are the cause of loss of macular function in age-related macular degeneration 
(AMD), the leading cause of blindness in the elderly worldwide. AMD 
accounts for 8.7% of global blindness and its prevalence is likely to increase 
as a consequence of exponential population ageing. The projected number of 
people with the disease is 196 million in 2020, increasing to 288 million in 
2040 (Wong et al., 2014). 
Review of the literature 
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AMD is characterized by a progressive loss of central vision attributable to 
degenerative and neovascular changes in the macula, the highly specialized 
region of the retina responsible for fine visual acuity. The macula constitutes 
only a small part of the retinal area (about 4%), but it accounts for almost 
10% of the entire visual field (Kolb et al., 2014). The typical signs of early 
AMD are pigmentary changes and/or the appearance of white-yellow 
deposits called drusen in the fundus of patients. Drusen, whose origin is still 
unknown, are aggregates of lipids, proteins and extracellular material that 
accumulate between the RPE and the Bruch’s membrane (Crabb et al., 
2002). Late AMD is characterized by diffuse atrophy of RPE cells (dry AMD) 
and/or choroidal neovascularization (wet AMD); if left untreated, wet AMD 
usually causes legal blindness within months after the second eye becomes 
affected, in contrast, these events may take years in patients with dry AMD. 
AMD is a complex multifactorial disease and the reasons for RPE dysfunction 
have not yet been identified, although a variety of possible causes have been 
recognized including genetic factors (genetic contribution is identified in up 
to 25% of AMD cases) (Seddon et al., 1997), ischemia, oxidative stress, 
phagocytic overload, cigarette smoke, lipofuscin toxicity, inflammation, and 
microbial infection (Zarbin, 2004). 
Therapeutic approaches to AMD have been mostly focused on the wet 
form of the disease, because the pathogenic mechanisms of dry AMD are still 
unclear. Wet AMD is currently treated with the intraocular administration of 
anti-neovascular agents that block VEGF binding to its receptor on 
endothelial cells, thus preventing neovascularization. Moreover the risk of 
progression to advanced neovascular AMD is reduced with the oral 
supplementation of high levels of antioxidants and zinc (AREDS formulation: 
vitamin C, vitamin E, β-carotene, and zinc) (Kassoff et al., 2001). While 
intravitreal antiangiogenic therapy has been the most effective therapeutic 
strategy so far, it is beneficial only for less than 50% of patients with wet 
AMD, and therefore less than 5% of all AMD patients (Rosenfeld et al., 2006, 
Kolb et al., 2014, Gragoudas et al., 2004, Algvere et al., 2008). Thus, despite 
the significant advances with anti-VEGF therapy in slowing the progression 
of wet AMD, there is still a large unmet medical need for many patients who 
have already lost vision from this condition and for the vast majority of AMD 
patients suffering from RPE geographic atrophy. 
2.2 WHAT ARE BIOLOGICS? 
Biologics, also called biopharmaceuticals, are medicinal products produced 
by biotechnology comprised of proteins such as hormones, enzymes, or 
monoclonal antibodies, but also gene and cell therapy products. Like all 
medicines, biologics work by interacting with the body to produce a 
therapeutic outcome. Many, but not all biologics are made using genetically 
modified cells; their complex manufacturing processes are very sensitive, and 
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precise control is required to obtain consistent results and to guarantee the 
safety and efficacy of the final product. Recombinant human insulin was the 
first biologic approved in the United States in 1982. Prior to that, protein 
products approved for use in humans were extracted from natural sources 
(Samanen, 2013). Biologics are the fastest growing sector of the 
pharmaceutical industry, with total global market sales in 2011 of about $ 115 
billion (including vaccines), which represents about 16% of the gross 2011 
prescription drug sales estimated at about $ 710 billion (Carton and Strohl, 
2013). 
Having defined what biologics are, the second question that arises is how 
do they differ from synthetic drugs? The key differences lie in the size, 
manufacturing techniques, physicochemical properties, pharmacokinetics 
and pharmacodynamics properties, and route of administration (table 2). 
Table 2. Key differences between biologics and synthetic drugs. 
Property Biologics Synthetic drugs 
Size Large, > 1000 Da Small, < 500 Da 
Manufacture Biologically produced Chemical synthesis 
Physicochemical properties Complex and variable, 
undergo post-transcriptional 
modifications, e.g. 
glycosylation 
Mostly well defined 
Route of administration Parenteral administration Oral administration 
 
Genentech has compared the difference in size and complexity between 
aspirin (21 atoms) and an antibody (>20 000 atoms) to the difference 
between a bike (10 kg) and a business jet (> 10 000 kg). This example well 
portrays the problems encountered in the delivery of biologics to the site of 
action; their large size prevents them from crossing biological barriers, and 
their inherent physicochemical complexity makes them unstable and prone 
to degradation. Consequently, there is a compelling need to design delivery 
systems that allow the safe and effective delivery of biologics to their site of 
action. In the following chapters the ocular delivery of selected biologics, 
including genes, cells, and recombinant therapeutic proteins, will be 
discussed in more detail. 
2.3 GENE THERAPY 
2.3.1 THE ROCKY ROAD TO GENE THERAPY 
Gene therapy is a medical procedure that attempts to correct a genetic defect  
(such as a lacking or malfunctioning gene sequence), to increase the 
production of a therapeutic protein or to render cells susceptible to the 
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body’s own defence mechanisms or drug treatment, by replacing a defective 
gene with a normal gene. The major benefit of gene therapy is that it has the 
potential to provide a cure after a single intervention, since its beneficial 
effects may last a lifetime. The idea of treating human disease at a genetic 
level began to form in the mid-1960s, when the work with tumorigenic 
viruses of Renato Dulbecco and colleagues (Sambrook et al., 1968) 
established that in the course of transforming a cell from the normal to the 
neoplastic phenotype, the papovaviruses SV40 and polyoma integrated their 
genetic information stably and heritably into the genomes of target cells 
(Friedmann, 1992). This observation together with advances in DNA 
manipulation techniques, led to proposal that exogenous “good” DNA may be 
used to replace the defective DNA in those who suffer from genetic defects 
(Friedman and Roblin, 1972). 
The first gene therapy clinical trial was approved in 1989 (Rosenberg et 
al., 1990) and in the following years several other trials followed, until in 
1999 an 18-year-old trial participant who had an unusually mild form of liver 
disease caused by mutations in a gene on the X chromosome, died 4 days 
after receiving an injection of an adenovirus carrying the corrected gene 
(Raper et al., 2003). This death and other tragic adverse events, including 
treatment-induced leukaemia in some volunteers (Hacein-Bey-Abina et al., 
2008), suddenly debunked the initial excitement generated by the advent of 
gene therapy. Fortunately, despite many difficulties and waning interest in 
the field, gene therapy has recently experienced a revival among scientists 
and pharmaceutical companies, due to successful clinical trials for several 
types of immunodeficiency diseases (Gaspar et al., 2011a, Gaspar et al., 
2011b), haemophilia (Nathwani et al., 2011), cancer (Kaufman et al., 2010, 
Porter et al., 2011, Kalos et al., 2011), and eye disorders (Bainbridge et al., 
2008, Maguire et al., 2008, Cideciyan et al., 2008, MacLaren et al., 2014). 
Moreover in 2012 the European Medicines Agency approved the marketing 
application of Glybera, an adeno-associated virus engineered to express 
lipoprotein lipase in the muscle for the treatment of lipoprotein lipase 
deficiency, and first gene therapy treatment to win approval by western 
regulators. 
2.3.2 AN EYE ON GENE MEDICINES 
Ophthalmology is one of the branches of medicine where gene medicines 
show great promise and, in recent years gene therapy has emerged as a novel 
approach for the treatment of many retinal disorders that are considered 
incurable. The eye offers several advantages as a target for gene therapy, 
since a) it is an immune-privileged site, thus the likelihood of systemic 
immune response is decreased, b) it is small and well defined, this allows for 
localized treatment with smaller doses, and consequently reduced chance of 
systemic absorption and toxicity, and c) the effects of localized ocular 
treatments can be easily observed and monitored for efficacy. 
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The only gene medicine approved so far for ocular treatment is 
pegaptanib (Macugen), a 28-base RNA aptamer, developed to bind and block 
the activity of extracellular VEGF, specifically the 165-amino-acid isoform 
(VEGF165) (Gragoudas et al., 2004). In order to allow for a 6 weeks 
administration interval, the aptamer is covalently linked to two branched 20 
kDa PEG moieties that increase its intravitreal half-life and the sugar 
backbone has been modified to prevent nuclease degradation (Ruckman et 
al., 1998). To date, 31 gene therapy clinical trials for ocular diseases, 
including AMD, choroideremia, Leber’s hereditary optic neuropathy, retinitis 
pigmentosa, Leber’s congenital amaurosis, superficial corneal opacity, 
glaucoma, Stargardt’s disease, and diabetic macular edema, have been 
initiated (source The Journal of Gene Medicine Clinical Trial site). While 
most trials are still in the early phases, one AAV-based gene therapy trial for 
Leber’s congenital amaurosis is currently in advanced development with 
safety and efficacy being evaluated in a phase III clinical trial. 
Viral gene therapy is still the most popular choice for gene therapies now 
in development, and adeno-associated virus (AAV) is the most successful 
vector used so far. Indeed, viruses such as lentiviruses, adenoviruses, 
retroviruses and the aforementioned adeno-associated viruses, work as 
natural syringes that inject genetic material into cells very effectively. 
However, despite being stripped of disease-causing elements, viruses are 
pathogens and safety concerns, together with difficulties of production on a 
large scale and low packaging capacity, have led to the search of alternative 
approaches. 
Non-viral gene delivery systems have the potential to provide nucleic 
acid-based therapeutics that closely resemble traditional pharmaceuticals. 
That is, the products should be 1) capable of being administered repeatedly 
with little immune response, 2) produced in large quantities with high 
reproducibility and acceptable cost, 3) stable to storage, and 4) easy to 
administer to patients (Davis, 2002). Other advantages of non-viral methods 
include very low frequency of integration, and the possibility to pack very 
large genes into the delivery system. Notwithstanding these favourable 
conditions, the widespread use of non-viral gene delivery systems is still 
hampered by a lack of efficacy, especially in vivo, attributable to the inability 
of these vectors to overcome the numerous barriers encountered between the 
site of administration and intracellular localization. 
2.3.3 MAKING NON-VIRAL SYSTEMS MORE EFFECTIVE 
Gene delivery in vitro is hampered by barriers present both outside and 
inside cells. Shortcomings arise due to the physicochemical characteristics of 
the genetic material itself, including susceptibility to degradation by 
nucleases, presence of bacterial motifs (i.e. in plasmid DNA), large size, and 
highly negative charge. Intracellular barriers encountered by non-viral gene 
delivery systems include low cellular uptake, entrapment inside lysosomes, 
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cytoplasmic degradation and poor translocation kinetics, low nuclear 
targeting (for gene therapeutics requiring nuclear entry), and loss of genetic 
material leading to short gene expression. Moreover, the majority of gene 
delivery systems are cationic and therefore prone to non-specific interactions 
with negatively charged cell surface molecules such as glycosaminoglycans. 
These non-specific interactions will have deleterious effects in vivo and 
lead to biased biodistribution, compromised stability, and lack of cellular 
specificity. Strategies to enhance the efficacy, specificity, and temporal 
control of non-viral gene delivery rely on the improvement of the delivery 
vectors as well as the modification of DNA itself (summarized in table 3). 
Table 3. Genetic material optimization and vector design can improve transgene 
expression; commonly used strategies to overcome transfection bottlenecks. 
Optimization of genetic material Vector design 
Problem Solution Problem Solution 
Loss of 
plasmid 
Episomal replication (i.e. 
EBNA-1, S/MAR) 
Poor uptake Decrease size 
Site specific integration 
(i.e. TALENs, 
transposons) 
Membrane 
penetrating agents 
(i.e. CPPs) 
Promoter 
shutdown 
Alternative promoters 
(i.e. non-viral promoters, 
cell specific promoters) 
Receptor-mediated 
uptake (i.e. CD44, 
transferrin, LDL) 
Bacterial 
motifs
1
 
Minimize GC content Lysosomal 
entrapment 
Pore forming 
peptides (i.e. 
toxins, CPPs) 
Remove bacterial 
backbone (minicircle 
DNA) 
Fusogenic lipids 
and peptides (i.e. 
DOPE, GALA) 
DNA 
degradation 
DNA topology 
(supercoiled DNA) 
pH-buffering effect 
(i.e. PEI) 
Nucleic acid analogs (i.e. 
morpholino) 
Low nuclear 
import 
Nuclear localization 
signal (i.e. Tat) 
Low nuclear 
import 
Nuclear localization 
signal (i.e. SV40 
enhancer) 
Non-specific 
interactions 
Shielding moieties 
(i.e. PEG, HPMA) 
Active targeting 
(i.e. RGD) 
1 Can elicit inflammation, cell death, and silencing (Mitsui et al., 2009) 
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2.4 CELL THERAPY AND TISSUE ENGINEERING 
2.4.1 GROWING NEW TISSUES TO REPLACE MALFUNCTIONING 
ONES 
In cell therapy, cells are injected into patients with the aim to restore, 
maintain, or improve tissue function. Cells can either be delivered as 
suspensions, or they are first grown in vitro into complete and functional 
tissue units in conjunction with biomaterial scaffolds, and then they are 
implanted once the engineered tissues have reached the desired properties. 
This latter technique is commonly referred to as tissue engineering. The 
potential impact of this field is significant—in the future, engineered tissues 
could reduce the need for organ replacement, and greatly accelerate the 
development of new drugs that may cure patients, eliminating the need for 
organ transplants altogether (Griffith and Naughton, 2002). 
Blood transfusions, first successfully performed by James Blundell in 
1818 to treat haemorrhages after childbirth, were the first type of cell 
therapy. Thereafter, in the late 1950s E. Donnall Thomas pioneered the 
development of bone marrow transplantation to treat leukaemia and other 
blood disorders. A decade later artificial skin for the treatment of burns was 
the first engineered tissue being developed (Hall et al., 1966, Spira et al., 
1969). Unfortunately, the success of engineered dermal implants for treating 
skin injuries and burns has not been as easy to replicate for organs such as 
the liver and pancreas, partly because expanding hepatocytes or pancreatic 
islet cells in culture is much more difficult than expanding dermal fibroblasts 
or keratinocytes (Griffith and Naughton, 2002). Indeed, the source of 
replacement cells is of great importance for tissue engineering and ideally it 
should be readily available in sufficient quantity, not cause immunorejection 
and be safe for the recipient. 
Recent advances in stem cell biology have opened new avenues for tissue 
engineering. Human embryonic stem (hES) cells are characterized by their 
capacity for self-renewal and their ability to differentiate into all cell types 
found in adult tissues. Furthermore, the surprising discovery by Takahashi 
and Yamanaka (Takahashi and Yamanaka, 2006) that somatic cells can be 
reprogrammed into induced pluripotent stem (iPS) cells, has allowed 
scientists to have access to unlimited, immunocompatible, and ethically 
acceptable cell sources. The potential of iPS cells in regenerative medicine is 
undeniable; these cells can be derived from essentially any individual and, 
after genetic modification, patient-derived iPS cells may be transplanted 
back into the patient for therapeutic purpose. However, the safety of any 
stem cell-based therapy is a paramount concern, since these cells are known 
to develop into tumours in vivo. Indeed, there are clear similarities between 
the excitement generated by cell therapy and tissue engineering today and 
that generated by the advent of gene therapy a few decades ago. Hopefully, 
the lessons learned from the difficulties and failures of gene therapy will be 
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applied to the nascent field of regenerative medicine and thus facilitate the 
development of safe and effective therapies (Porteus, 2011). 
2.4.2 ENGINEERING VISION 
Cell therapies for eye diseases are advancing rapidly and, in the anterior part 
of the eye, have already been tested in hundreds of patients. For example, 
limbal stem cell transplantation is successfully used in the clinical practice 
for the treatment of chemical burns to the cornea (Eveleth, 2013). In this 
medical procedure, a small sample of corneal limbus, containing the limbal 
epithelial stem cell niche, is surgically harvested from a donor eye, these cells 
are then expanded in culture and transplanted to the recipient cornea, alone 
or with a biomaterial scaffold, and eventually the transplanted epithelial cells 
will repopulate and heal the damaged cornea (Pellegrini et al., 1997, Rama et 
al., 2010). 
As in the case of gene therapy, the eye is an ideal setting for the 
implementation of cell-based therapies, because a small number of 
transplanted cells may be sufficient to achieve a therapeutic effect, the 
transplantation of donor cells to precise locations is possible with help of 
direct microscopic visualization, the fate of transplanted cells can be followed 
in animals by non-invasive imaging techniques such as two-photon 
microscopy (Palczewska et al., 2014), allogenic cells are less likely to be 
rejected due to ocular immune privilege, and, due to the presence of several 
ocular barriers, the migration of transplanted cells outside the eye ball is 
unlikely. 
There are a few cell therapies for retinal disease (dry AMD, Stargardt’s 
disease, and retinitis pigmentosa) in clinical development, moreover the first 
ever hES cell-derived therapy has been assessed in humans for safety and 
tolerability (Schwartz et al., 2012). These therapies focus on the 
reconstruction of photoreceptors and retinal pigment epithelial cells using 
hES cells and retinal progenitor cells. In the case of AMD, the rationale 
behind the reconstruction of a functional RPE monolayer is twofold, firstly 
the transplanted RPE would replace dysfunctional RPE, and secondly the 
powerful trophic effect that the RPE exerts on photoreceptors may delay cell 
degeneration (Eveleth, 2013). In the above mentioned trials, the replacement 
cells are delivered subretinally as a suspension; this straightforward 
approach may however not guarantee the survival and function of the 
transplanted cells in the hostile environment in the diseased eye. Moreover, 
the cellular arrangement of the injected cells will be difficult, if not 
impossible, to control. For these reasons, the transplantation of a polarized 
RPE monolayer as an intact epithelial sheet supported by a carrier substrate 
may prove to be a better approach. The potential medical applications of 
tissue engineered RPE monolayers go beyond cell therapy; these constructs 
may also provide a unique platform from which to study disease, identify new 
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drugs, and screen for their toxicity and permeation across the outer blood-
retinal barrier. 
Another emerging AMD treatment currently in clinical trials combines the 
technologies of gene and cell therapy into one platform, encapsulated cell 
technology (ECT). ECT is a biotechnical implant system where genetically 
engineered cells that produce specific bioactive substances (i.e. proteins) are 
enclosed into polymer scaffolds to create “drug factories” for long-term drug 
delivery. Neurotech’s ECT intravitreal implant of encapsulated human retinal 
pigmented epithelial cells releasing ciliary neurotrophic factor (CNTF) is 
currently in a phase II clinical trial for macular degeneration. 
2.5 PROTEIN THERAPEUTICS 
2.5.1 CHALLENGES OF PROTEIN THERAPY 
Compared to gene and cell therapy, protein therapeutics have enjoyed a 
much wider therapeutic success and are extensively used in the clinics to 
treat a broad range of illnesses, including cancer, autoimmune diseases, 
infectious diseases, and metabolic disorders. From a therapeutic perspective, 
proteins offer the distinct advantage of specific mechanisms of action and 
high potency (Pisal et al., 2010). Despite these attractive properties, proteins 
are notoriously challenging to develop and formulate due to chemical and 
physical instability, immunogenicity, and unfavourable pharmacokinetic 
properties. Protein stability can be compromised by several external factors 
such as pH, temperature, and surface interaction, as well as by contaminants 
and impurities from excipients (Frokjaer and Otzen, 2005), therefore 
stabilization of protein pharmaceuticals is of paramount importance to 
ensure their safety and efficacy. Indeed, protein instability, together with low 
permeability across biological membranes, are the two main reasons why 
proteins have to be administered parenterally rather than taken orally like 
most small molecule drugs. Moreover protein therapeutics must usually be 
stored at low temperatures or freeze-dried to achieve an acceptable shelf life 
(Wei, 1999). The pharmaceutical and pharmacokinetic properties of proteins 
can be optimized by different approaches; for example, by mutagenesis, 
chemical modification or by designing specific drug-delivery systems. 
However, most protein-based drugs today are still formulated as suspensions 
or aqueous solutions (Frokjaer and Otzen, 2005). 
2.5.2 PROTEINS REVOLUTIONIZE THE TREATMENT OF WET AMD 
Therapeutic proteins have found an extraordinary development in 
ophthalmology and intravitreal anti-angiogenic therapy has become the gold 
standard for the treatment of choroidal neovascularization in wet AMD. In 
2006 the FDA approved ranibizumab (Lucentis), a 48 kDa fragment of a 
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recombinant monoclonal antibody that binds to and inhibits the vascular 
endothelial growth factor A (VEGF-A), for the treatment of wet AMD. 
Ranibizumab was the first therapy for neovascular AMD to result in vision 
loss prevention and moderate improvement in visual acuity (Rosenfeld et al., 
2006, Brown et al., 2006). 
Before the approval of ranibizumab, some ophthalmologists began 
administering bevacizumab (Avastin), a 149 kDa recombinant monoclonal 
antibody closely related to ranibizumab, off-label to treat patients with ocular 
neovascular diseases. Bevacizumab, which received its first approval in 2004 
for the treatment of metastatic colorectal cancer, is manufactured by the 
same company as ranibizumab; however the low dosage needed in the eye 
(compared to the amounts required in colon and other cancers) make it 
much cheaper to use with similar efficacy (Martin et al., 2011). 
Most recently, in 2011 aflibercept or VEGF Trap (Eylea), a recombinant 
soluble VEGF receptor protein (115 kDa) in which the binding domains of 
VEGF receptors 1 and 2 are combined with the Fc portion of 
immunoglobulin-G (Nguyen et al., 2006), has also been approved for CNV in 
wet AMD. Unlike pegaptanib, ranibizumab, and bevacizumab, which all act 
through inhibition of VEGF-A, aflibercept is designed to inhibit all members 
of the VEGF family (Chappelow and Kaiser, 2008), as well as placental 
growth factor 1 and 2 (Nguyen et al., 2006). 
Ongoing clinical trials with therapeutic proteins for ocular diseases are 
focused not only on blocking neovascularization, but also on inhibiting 
complement pathway, on reducing inflammation and on conferring 
neuroprotection.  
2.5.3 A CLOSER LOOK AT THE OCULAR PHARMACOKINETICS OF 
PROTEINS 
Despite the widespread use and undisputed efficacy of intravitreally 
administered anti-VEGF antibodies, an obvious but not easily answered 
question remains: how are these large proteins and other biologics diffusing 
in the vitreous, penetrating the various retinal layers, and finally being 
eliminated from the eye? The diffusion of drugs in the vitreous is mainly 
dependent on their molecular weight and lipophilicity; due to their high 
molecular weight, biologics tend to have a slower diffusion and longer 
residence time in the vitreous compared to small molecule drugs. Moreover, 
due to the presence of hyaluronan, a negatively charged glycosaminoglycan, 
cationic macromolecules may aggregate and be immobilized in the vitreous, 
losing thereby their activity. This is the case with cationic non-viral gene 
delivery systems, which are completely inactivated when administered 
intravitreally (Pitkanen et al., 2004, Peeters et al., 2005). 
The elimination of drugs from the vitreous follows first order kinetics and 
occurs by two major routes (figure 2): the anterior route (dashed arrows) via 
aqueous drainage through the anterior chamber, and the posterior route 
 25 
(leftwards arrows), proposed to be the primary route for small and lipophilic 
molecules, as it requires adequate passive permeability or active transport 
across the retina and retinal pigment epithelium (Maurice and Mishima, 
1984, Urtti, 2006). The posterior route causes a quicker elimination of the 
drug compared to the anterior route because the bottleneck between the lens 
and ciliary body is replaced by the large surface area in the posterior segment 
of the eye (Maurice and Mishima, 1984). 
 
 
Figure 2 Elimination of intravitreally administered drugs. The posterior route (leftwards 
arrows) via the retina and RPE is favoured by small and lipophilic molecules, and 
promotes a quick elimination from the vitreous. This elimination pathway is 
precluded to hydrophilic drugs and macromolecules due to the biological barriers 
found in the ocular posterior segment. The anterior route (dashed arrows), through 
the posterior chamber, anterior chamber and via the trabecular meshwork to the 
canal of Schlemm, is accessible to all drugs, but it is slower due to the bottleneck 
between the lens and ciliary body. 
Biologics are usually large hydrophilic molecules, therefore their elimination 
after intravitreal administration is expected to follow the less effective 
anterior route, and consequently their half-life in the vitreous tends to be 
prolonged compared to small molecule drugs. Nevertheless, studies with 
animal models have found that the full length antibody bevacizumab can 
permeate through all retinal layers and even reach the choroidal blood 
vessels (Shahar et al., 2006, Heiduschka et al., 2007), thereby challenging 
the classic assumption that large drug substances cannot be eliminated via 
retinal clearance. This observation may be explained by the presence of an 
active transport mechanism that promotes the elimination of antibodies from 
the eye (see below).  
Unfortunately, comprehensive studies on human ocular pharmacokinetics 
of proteins and other biologics are lacking. Rabbits and monkeys are 
commonly used in ocular pharmacokinetic studies; however differences in 
ocular anatomy have led to criticism on the reliability of pharmacokinetic 
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data obtained from animal models. In humans, the vitreous volume is 
approximately 4 ml and, depending on age, its composition is 40% to 80% 
gel (Balazs, 1982, Sebag, 1987), whereas it is smaller in rabbits (1.5 ml) and 
monkeys (1.5-3.2 ml), but with higher vitreous gel content (100% in rabbits 
and 60% in rhesus monkeys). These interspecies differences have been used 
to explain the shorter vitreal half-lives of VEGF-inhibitors obtained from 
animal experiments compared to human data (table 4). 
Table 4. Intravitreal half-lives of anti-VEGF inhibitors in humans and rabbits. 
Drug Mw (kDa) t1/2 in humans (days) t1/2 in rabbits (days) 
Pegaptanib 50 8 (Basile et al., 2012) 3.5 (Martin et al., 
2002) 
Ranibizumab 48 7.2-9 (Krohne et al., 
2012, Xu et al., 2013) 
2.9 (Bakri et al., 
2007a, Gaudreault et 
al., 2007) 
Bevacizumab 149 6.7-10 (Krohne et al., 
2008, Zhu et al., 
2008) 
4.3-6.0 (Bakri et al., 
2007b, Nomoto et al., 
2009) 
Aflibercept 115 no published data 4.6 (Christoforidis et 
al., 2012) 
 
Del Amo and colleagues (E. del Amo, K.S. Vellonen, H. Kidron, A. Urtti, In 
Silico Prediction of Intravitreal Primary Pharmacokinetic Parameters and 
Drug Concentrations: Tool for Ocular Drug Development. Pharm Res, 
submitted), however argue that the anatomical differences between the 
rabbit and human eye do not compromise ocular pharmacokinetic data and 
indeed, the reported differences in the half-lives are fairly small. The 
intravitreal half-life t1/2 of a drug in the vitreous is described by following 
equation: 
(1) t1/2 = (ln2 x Vss)/Cl 
where Vss is the intravitreal volume of distribution and Cl is the intravitreal 
clearance. Vss is expected to be approximately two times greater in the 
human eye compared to the rabbit eye. The Cl in the human eye is also 
expected to be increased 2-3 fold based on the larger RPE surface area, 
therefore the higher Vss and Cl values may compensate for each other, 
leading to similar half-lives. 
Table 4 also shows that, unexpectedly and despite the 3-fold difference in 
molecular weight, the intravitreal half-lives of ranibizumab (48 kDa) and 
bevacizumab (149 kDa) in humans are similar. Since the diffusion and 
elimination of a drug from the vitreous depend on its molecular weight, as 
well as its lipophilicity, one would expect that the larger full-sized IgG 
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bevacizumab would have a longer residence time in the vitreous compared to 
ranibizumab. This conflicting observation has been explained by the activity 
of the neonatal Fc receptor, which is known to bind IgG antibodies and 
transcytose them across tissue barriers (Rodewald and Kraehenbuhl, 1984, 
Simister and Rees, 1985). RPE cells express ocular neonatal Fc receptor (van 
Bilsen et al., 2011), therefore it is reasonable to assume that this active 
outwards transport mechanism from the retina to the blood circulation may 
contribute to a quicker elimination of bevacizumab, but not ranibizumab, 
from the vitreous. Furthermore the recycling function of neonatal Fc receptor 
on full-sized antibodies, may also explain the much longer plasma half-life of 
bevacizumab (20 days) (Lu et al., 2008) compared to ranibizumab (2 hours) 
(Xu et al., 2013). This very long systemic exposure to bevacizumab may lead 
to systemic inhibition of VEGF activity and undesirable side effects; indeed 
studies on patients receiving intravitreal injections of bevacizumab have 
shown suppression of systemic VEGF over a time period of four weeks 
(Carneiro et al., 2012, Matsuyama et al., 2010, Sato et al., 2012, Zehetner et 
al., 2013). 
In conclusion, despite the hundreds of thousands intravitreal injections of 
therapeutic proteins performed every year, the knowledge on their ocular 
pharmacokinetics, the influence of ageing and pathological conditions, and 
the possible effects of repeated intravitreal injections, is still lacking. This 
knowledge is essential to implement the design of controlled delivery 
systems, as well as to develop new biologics with improved ocular 
pharmacokinetic properties. 
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3 AIMS OF THE STUDY 
The thesis deals with the delivery of various biologics, including DNA, cells, 
and proteins to the retinal pigment epithelium, a monolayer of cells located 
underneath the retina in the back of the eye. The RPE is an interesting target 
from a pharmacological point of view, because RPE degeneration plays a 
central role in the pathogenesis of several degenerative retinal disorders that 
lead to irreversible vision loss. The specific aims were: 
 
1. The development of a standardized transfection protocol optimized 
for the efficient and reproducible non-viral gene transfer to RPE 
cells in vitro. 
 
2. The transfection of RPE cell models (ARPE-19, human primary 
RPE, and human embryonic stem cell-derived RPE) with non-viral 
gene delivery systems using the protocol developed in point 1. 
Transfection efficacy may be increased by the implementation of 
optimized genetic material and different carriers. 
 
3. The clarification of the cellular uptake mechanism of Tat peptide, a 
cell penetrating peptide commonly used for the delivery of 
biologics. The structure-activity relationship of Tat peptide is 
investigated by modifications of its amino acid sequence. 
 
4. The reconstruction of a functional RPE monolayer in vitro, by 
differentiation of human embryonic stem cells toward RPE on a 
transplantable, biopolymer coated polyimide membrane. 
 
5. The evaluation of the cytoprotective properties of heat shock 
protein 70 kDa (Hsp70) against oxidative stress in the RPE, and 
the feasibility of Hsp70 protein therapy as a therapeutic strategy to 
target aggregate-associated neurodegeneration in AMD. 
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4 OPTIMIZED TRANSFECTION PROTOCOL 
FOR EFFICIENT IN VITRO NON-VIRAL 
POLYMERIC GENE DELIVERY TO HUMAN 
RETINAL PIGMENT EPITHELIAL CELLS 
(ARPE-19). 
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5 TAT(48-60) PEPTIDE AMINO ACID 
SEQUENCE IS NOT UNIQUE IN ITS CELL 
PENETRATING PROPERTIES AND CELL-
SURFACE GLYCOSAMINOGLYCANS 
INHIBIT ITS CELLULAR UPTAKE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from Journal of Controlled Release, Vol 158, Astrid Subrizi, Eva 
Tuominen, Alex Bunker, Tomasz Róg, Maxim Antopolsky, Arto Urtti, Tat(48-
60) peptide amino acid sequence is not unique in its cell penetrating 
properties and cell-surface glycosaminoglycans inhibit its cellular uptake, 
277-285, Copyright 2012, with permission from Elsevier. 
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6 GENERATION OF HESC-DERIVED 
RETINAL PIGMENT EPITHELIUM ON 
BIOPOLYMER COATED POLYIMIDE 
MEMBRANES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from Biomaterials, Vol 33, Astrid Subrizi, Hanna Hiidenmaa, 
Tanja Ilmarinen, Soile Nymark, Peter Dubruel, Hannu Uusitalo, Marjo 
Yliperttula, Arto Urtti, Heli Skottman, Generation of hESC-derived retinal 
pigment epithelium on biopolymer coated polyimide membranes, 8047-
8054, Copyright 2012, with permission from Elsevier. 
Oxidative stress protection by exogenous delivery of rhHsp70 chaperone to the retinal pigment 
epithelium (RPE), a possible therapeutic strategy against RPE degeneration. 
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7 OXIDATIVE STRESS PROTECTION BY 
EXOGENOUS DELIVERY OF RHHSP70 
CHAPERONE TO THE RETINAL PIGMENT 
EPITHELIUM (RPE), A POSSIBLE 
THERAPEUTIC STRATEGY AGAINST RPE 
DEGENERATION. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from Pharmaceutical Research, Astrid Subrizi, Elisa Toropainen, 
Eva Ramsay, Anu J. Airaksinen, Kai Kaarniranta, Arto Urtti, Oxidative stress 
protection by exogenous delivery of rhHsp70 chaperone to the retinal 
pigment epithelium (RPE), a possible therapeutic strategy against RPE 
degeneration, Copyright 2014, with permission from Springer Science and 
Business Media. 
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8 SUMMARY OF THE MAIN RESULTS 
The main results presented in the publications are summarized in table 5. 
Table 5. Summary and implications of the main results. 
RPE transfection protocol (publication I) 
Optimal parameters 20´000 cells/well (96 wp), PEI/DNA ratio 2/1 (= n/p 10), Mes-
Hepes buffer, 1-2 h incubation with cells. 
Expected outcome 10-20 ng/ml RL protein (DNA dose 600 ng), 60-80% cell 
viability. 
This protocol provides a relatively simple and reproducible procedure for the pre-selection of 
potential candidate reagents as non-viral gene delivery systems to the RPE. 
 
Cell penetrating properties of Tat peptide (publication II) 
Interaction with model 
membrane 
Could not predict the cellular behaviour of Tat peptide. 
Amino acid sequence May be modified without loss of activity, as long as the number 
of positive charges does not change. 
Cell uptake Occured by endocytosis, possibly also phagocytosis. No direct 
translocation across the plasma membrane was observed. 
Effect of 
glycosaminoglycans 
Inhibited Tat upake. 
The usefulness of Tat peptide as a tool for the delivery of biologics is questionable due to the 
lack of cellular specificity and lysosomal entrapment. 
 
RPE tissue engineering (publication III) 
Polyimide membrane 
suitability 
Required coating with bioadhesive molecules to support growth 
and maturation of hESC-RPE. 
Bioadhesive molecules Laminin and collagen type I and IV provided suitable coating. 
Characteristics of tissue 
engineered RPE 
Cobblestone morphology, highly pigmented, polarity (apical 
localization of Na/K-ATPase and MERTK), expression of RPE-
specific marker proteins (MITF, PMEL, TYR, RPE65, BEST, 
PEDF, CRALBP), formation of tight junctions (ZO-1) and barrier 
function which was moderately leakier than the normal RPE 
tissue, phagocytic activity. 
hESC-RPE grown on polyimide membranes may be useful for in vitro drug screening, cell 
replacement therapy and disease model development, provided that the time required to 
generate these tissues is shortened. 
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Hsp70 therapy against oxidative stress in the RPE (publication IV) 
Effect of Hsp70 
treatment 
Hsp70 protected ARPE-19 cells from oxidative stress by 
reducing inflammation, increasing cell viability, and decreasing 
cytolysis. 
In vitro uptake and 
localization of Hsp70 
Exogenously delivered Hsp70 was internalized by dividing and 
differentiated ARPE-19 cells and was localized in late 
endosomes and lysosomes. 
Intraocular distribution 
ex vivo 
Intravitreally administered Hsp70 diffused to the retina and the 
RPE. 
Hsp70 therapy may provide a possible therapeutic strategy against degeneration of RPE cells 
in AMD. 
 
Unpublished results 
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9 UNPUBLISHED RESULTS 
In addition to the published work, following unpublished transfection results 
are also included in the thesis. Transfections were carried out following the 
published protocol (publication I). ARPE-19 human retinal pigment 
epithelial cell line, human primary RPE cells, and hESC-RPE human 
embryonic stem cell-derived RPE, were used as RPE cell models. 
Optimization of the genetic material was achieved using three different 
strategies: 1) introduction of genetic elements favouring the episomal 
replication of the plasmid (EBNA-1 plasmid) (Hung et al., 2001); 2) use of 
the alternative non-viral promoter human elongation factor-1 alpha (EF1a); 
and 3) elimination of bacterial plasmid DNA sequences (minicircles) (Kay, 
2011). Different carriers, including cationic DOTAP/DOPE/PS fusogenic 
liposomes (Mannermaa et al., 2005) and amphiphilic block copolymer core-
shell micelles (Alhoranta et al., 2011) were tested for transfection efficacy and 
compared to branched polyethylenimine (PEI, 25 kDa) (Boussif et al., 1995). 
The size of the carrier/DNA complexes was 100-250 nm. The carrier to DNA 
ratios were chosen after observation of the complexation on electrophoresis 
gels and after following the release of DNA from the complexes upon 
exposure to dextran sulphate (Xu and Szoka, 1996). A selection of the 
transfection results is provided. 
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9.1 EFFECT OF EBNA-1 ON THE TRANSFECTION OF 
DIFFERENTIATED ARPE-19 CELLS GROWN ON 
LAMININ-COATED TRANSWELL FILTERS 
The introduction of EBNA-1 genetic elements (figure 3) prolonged the 
secretion of the transgene (dashed lines) even in non-dividing cells, 
compared to non-replicating plasmid (solid lines). 
 
(a) PEI +8 polyplexes  (b) DOTAP/DOPE/PS lipoplexes 
Figure 3 Effect of EBNA-1 on transfection of differentiated ARPE-19 cells. Transgene 
secretion curves of cells transfected with EBNA-1 plasmids are presented as 
dashed lines, in comparison, transgene secretion curves of cells transfected with 
regular non-episomal plasmids are presented as solid lines. The full symbols 
represent apical secretion and the empty symbols represent basolateral secretion. 
(a) Transfection with PEI polyplexes, and (b) transfection with dotap/dope/ps 
lipoplexes. 
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9.2 MINICIRCLE EFFICACY AND INFLUENCE OF 
PROMOTER COMPARED TO EBNA-1 PLASMID ON 
THE TRANSFECTION OF HESC-RPE CELLS 
The transfection with minicircles increased transgene production compared 
to plasmid DNA containing EBNA-1 genetic elements. For PEI polyplexes 
(figure 4 a), the secretion of the transgene decreased significantly two weeks 
after transfection, while lipoplexes (figure 4b) still maintained a detectable 
protein secretion level 20 days after transfection. In the case of polyplexes, 
the use of non-viral promoter EF1a did not prevent promoter shutdown; in 
the case of lipoplexes, instead, the use of EF1a promoter drove stable 
transgene secretion for up to 20 days. 
 
(a) PEI + 10 polyplexes  (b) DOTAP/DOPE/PS lipoplexes 
Figure 4 Effect of minicircle vs regular plasmid (EBNA-1) and influence of the promoter 
on transgene secretion. Transgene secretion curves of cells transfected with 
EBNA-1 plasmids are presented as dashed lines, transgene secretion curves of 
cells transfected with minicircles are presented as solid lines. The empty symbols 
represent minicircles with viral CMV promoter, the full symbols represent minicircles 
with human EF1a promoter. (a) Transfection with PEI polyplexes, and (b) 
transfection with dotap/dope/ps lipoplexes. 
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9.3 AMPHIPHILIC BLOCK COPOLYMER CORE-SHELL 
MICELLES PROMOTE HIGHER TRANSFECTION 
EFFICIENCY AND PROTEIN SECRETION FOR UP TO 
18 DAYS IN HUMAN PRIMARY RPE 
Amphiphilic block copolymer core-shell micelles (dashed lines) showed 
increased transfection efficacy in human primary RPE compared to PEI 
polyplexes (solid lines, full symbol) and DOTAP/DOPE/PS lipoplexes (solid 
lines, empty symbol): cells secreted higher amounts of transgene for a longer 
period of time (figure 5). 
 
Figure 5 Effect of carrier on the transfection of human primary retinal pigment 
epithelial cells. Transgene secretion curves of cells transfected with minicircles 
carrying CMV promoter. Cells transfected with micellar nanoparticulates, linear (full 
symbol) and star (empty symbol) poly(n-butyl acrylate) – 2-(dimethylamino)-ethyl 
methacrylate, PDMAEMA-PBuA-PDMAEMA and (PBuA-PDMAEMA)6, respectively, 
are presented as dashed lines. In comparison, PEI polyplexes (solid line, full 
symbol) and DOTAP/DOPE/PS lipoplexes (solid line, empty symbol). 
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10 DISCUSSION 
Biologics are a new category of drugs, which have emerged rapidly in the 
drug discovery pipeline in the last two decades. The first insulin-related 
biologics that came to the market already 30 years ago, have paved the way 
for the development of a wide variety of biotechnologically produced drugs, 
including monoclonal antibodies, growth factors, genetic material and cell 
therapeutics. Since the approval in 2002 of adalimumab (Humira), a TNFα 
inhibitor for the treatment of rheumatoid arthritis, human or humanized 
monoclonal antibodies are the most prevalent and fast-growing category of 
biologics (Nelson et al., 2010). Indeed in the field of ophthalmology, the 
humanized monoclonal antibody/antibody fragment bevacizumab and 
ranibizumab are the therapy of choice for the treatment of age-related 
macular degeneration, a disorder of the posterior eye and leading cause of 
blindness in the elderly in the western world. Moreover biologics have also 
been used off-label to treat another vision threatening disorder, uveitis or 
ocular inflammation disease (Lim et al., 2006, Imrie and Dick, 2007). 
This thesis focuses on the delivery of different biologics to the retinal 
pigment epithelium, the monolayer of pigmented cells joined apically with 
tight junctions that forms the outer blood-retinal barrier in the eye. The RPE 
is an interesting target for biologics because its function is essential for 
retinal homeostasis and RPE atrophy leads to irreversible vision loss. Given 
its strategic position between the retina and the choroidal blood vessels, 
multiple therapeutic interventions targeting the RPE can be envisioned; 1) 
the transfection of transgenes coding for neurotrophic factors may help to 
maintain the viability of photoreceptors in the retina, while anti-angiogenic 
factors may prevent the uncontrolled growth of blood vessels from the 
choroid, 2) the delivery of therapeutic proteins may prevent RPE 
degeneration, and 3) a tissue engineered RPE monolayer may provide a 
replacement, if the tissue in situ is beyond repair. In the following 
paragraphs a general discussion touching upon these three main therapeutic 
approaches is presented. 
Non-viral ocular gene transfer to the RPE after intravitreal injection is 
challenging; polyplexes and lipoplexes have to travel a relatively long 
distance from the administration site and numerous ocular barriers may 
prevent their arrival to the target cells (Peeters et al., 2007). The first barrier 
encountered by the complexes is the vitreous itself; this complex and 
negatively charged three-dimensional network of collagen fibrils, 
glycosaminoglycans, and noncollagenous structural proteins, is known to 
immobilize cationic nanoparticulate systems and completely block gene 
expression of polyplexes and lipoplexes (Pitkanen et al., 2003, Peeters et al., 
2005). The mobility of cationic complexes in the vitreous can be improved 
through PEGylation (Peeters et al., 2005, Bochot et al., 2002); indeed 
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pegaptanib (Macugen), the 28-base RNA aptamer and only gene medicine 
approved so far for ocular treatment, is covalently linked to two branched 20 
kDa PEG moieties that increase its intravitreal half-life and the sugar 
backbone has been modified to prevent nuclease degradation (Ruckman et 
al., 1998). Another barrier encountered by non-viral gene delivery systems in 
their journey from the vitreous to the RPE is the neural retina; the retina 
limits the delivery of polymeric and liposomal DNA complexes to the RPE 
(Pitkanen et al., 2004), possibly by steric hindrance. The final extracellular 
barrier consists in the glycosaminoglycans found in the interphotoreceptor 
matrix and on the surface of RPE cells. RPE cells constantly synthesize and 
secrete glycosaminoglycans such as chondroitin sulphate, dermatan 
sulphate, and hyaluronic acid (Edwards, 1982); and these polyanions have 
been found to pose an important barrier to non-viral gene transfer (Ruponen 
et al., 2004). 
Cell penetrating peptides (CPPs) are often employed to deliver biologics, 
genes and proteins, to the desired targets in vitro and in vivo (Gait, 2003, 
Lindsay, 2002, Zhao and Weissleder, 2004, Schwarze et al., 1999). Could 
coupling of biologics to CPPs facilitate their delivery to the RPE after 
intravitreal injection? Or in other words, can the intraocular barriers be 
overcome with the help of CPPs? The most intensely studied yet least 
understood peptide is Tat peptide. Our study aimed at elucidating Tat 
peptide’s mechanism of cell penetration, and at distinguishing the amino 
acids in its sequence that are essential for its function from those that can be 
changed without affecting cell permeation efficacy. After synthesizing sixteen 
Tat peptide analogues bearing the same charge as the original Tat sequence, 
and testing them for cellular uptake in three cell lines, we came to the 
conclusion that it is not the sequence of Tat per se that dictates cell uptake, 
but the cationic charge of the peptide. Upon confocal microscope inspection, 
all the peptides were trapped inside lysosomes and direct penetration across 
the cell membrane was not observed for any peptide. Furthermore, our study 
showed that, similarly to non-viral gene delivery systems, 
glycosaminoglycans inhibit the cellular uptake of Tat peptide. Unfortunately, 
these results do not vouch for the usefulness of Tat peptide in helping to 
overcome the intraocular barriers. On the contrary, its cationic charge may 
hamper its diffusion in the vitreous, as well as make the targeting of the 
biologic to the RPE more difficult, since any anionic structure on the surface 
of cells will attract the CPP and its cargo. Furthermore, biologics requiring 
cytoplasmic or nuclear delivery will be instead targeted to the endosomes and 
eventually be degraded inside lysosomes. 
In order to avoid the ocular barriers discussed in the previous paragraphs, 
we chose to follow an ex vivo approach, where the transfection of RPE cells 
occurs outside the eye in a culture. This technique is also beneficial because it 
does not require targeting to a particular tissue, and the risk of adverse 
reactions due to an unintended dissemination of the vector is avoided. The 
first aim was to develop a standardized protocol optimized for the 
Discussion 
78 
transfection of retinal pigment epithelial cells (ARPE-19) in vitro. We 
employed a stepwise approach by addressing the following parameters and 
studying their effects on the final transfection outcome: cell density at 
seeding, PEI/DNA charge ratio, composition of the preparation buffer and 
polyplex assembly conditions, and incubation time of the complexes with 
cells (see table 6). 
Table 6. Parameters tested for the optimization of the transfection protocol. 
Tested parameter Optimal parameter 
Cell density at seeding 
4’000, 8’000, 20’000 cells/well in a 96 wp 
20’000 cells/well gave the highest protein 
production and lowest cytotoxicity 
PEI/DNA charge ratio
1 
1/1, 2/1, 4/1 
Charge ratio 2/1 was less toxic and more 
efficient 
Polyplex assembly conditions 
Diluted, concentrated (see text) 
No substantial differences. Diluted  
conditions allowed for better mixing. 
Polyplex preparation buffer 
mqH2O, Mes-Hepes buffered saline 
Polyplexes prepared in Mes-Hepes 
buffered saline were more efficient. 
Incubation time of the complexes with cells 
30 min, 1 h, 2 h, 5 h, 12 h, 24 h 
1-2 h incubation time gave the best results 
1 Charge ratio 2/1 corresponds approximately to n/p ratio 10. 
 
The cell density at seeding remarkably affected the transfection outcome, and 
20’000 cells per well, which yielded a sub-confluent (80%) culture after 
overnight incubation, gave the highest transfection efficacy and lowest 
cytotoxicity. The charge ratio of the polyplex influences the DNA 
condensation and the complex stability; in our setup the best charge ratio 
was 2/1. With PEI based nanoparticulates a significant proportion of the 
polymer utilized in the initial formation of the polyplex remains in the free 
form (Hanzlikova et al., 2011), and this may be partly responsible for the 
cytotoxicity. The composition of the nanoparticulate preparation buffer (pH 
and ionic strength) strongly affected gene expression; a higher level of 
transfection (500-fold) was achieved when polyplexes were prepared in 
isotonic Mes-Hepes buffered saline solution compared to distilled water. The 
preparation of the nanoparticulates in a more concentrated (i.e. mixing of 
250 μl cationic polymer with 250 μl plasmid DNA, with final dilution of the 
nanoparticulates at the desired volume after 2 h incubation at room 
temperature) versus diluted (i.e. mixing of 500 μl cationic polymer with 500 
μl plasmid DNA) conditions showed little effect on the transfection 
efficiency; however, especially in the case of small preparation volumes, we 
preferred to add the cationic polymer to plasmid DNA in diluted conditions 
because mixing was more effective. The incubation time of the 
nanoparticulates with ARPE-19 cells was of crucial importance to obtain high 
gene expression levels and minimal cytotoxicity; we found that an incubation 
time of 1 to 2 hours was optimal for our application. If shorter time was 
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applied, transfection efficiency was poor, while longer incubation periods 
caused cell toxicity. 
The optimized transfection protocol was utilized to test different carriers, 
including cationic DOTAP/DOPE/PS fusogenic liposomes (Mannermaa et 
al., 2005), and amphiphilic block copolymer core-shell micelles (Alhoranta et 
al., 2011), with RPE cells. The human retinal pigment epithelial cell line 
ARPE-19, primary human RPE and human embryonic stem cell-derived RPE 
(hESC-RPE) were used. Branched PEI 25 kDa was used as positive control. 
One of the shortcomings of non-viral gene transfer is that it tends to be short 
lived and the expression of the transgene is lost after a couple of days; 
however the expression of a curative transgene in situ should last months, if 
not years, in order to exert a lasting therapeutic effect. We have employed 
three different strategies aimed at the optimization of the genetic material to 
prolong gene expression; 1) the loss of plasmid was minimized by the 
addition to the plasmid sequence of genetic elements from Epstein-Barr virus 
(EBV), EBNA-1 and OriP that promote episomal replication (Hung et al., 
2001), 2) promoter shutdown was prevented by the use of the human 
promoter elongation factor-1 alpha (EF1a), and 3) the loss of transgene-
specific mRNA was minimized by the use of minicircle DNA that is devoid of 
bacterial plasmid DNA sequences and has lower CpG content (Kay, 2011). 
With these improved non-viral gene delivery systems we could transfect 
all RPE cell models, including the notoriously hard to transfect stem cells. 
The use of EBNA-1 plasmids was advantageous compared to non-replicating 
plasmids, as it considerably increased the length of transgene production for 
up to 2 months in non-dividing ARPE-19 cells. Furthermore minicircles were 
generally equally or better performing compared to EBNA-1 full plasmids, 
and the use of non-viral promoter EF1a further enhanced protein secretion 
time depending on the carrier used. The activity of different carriers was cell-
specific, and in the case of human primary RPE, amphiphilic block 
copolymer core-shell micelles were far superior compared to PEI polyplexes 
and DOTAP/DOPE/PS lipoplexes. 
These studies show that, despite being still inferior to viruses, non-viral 
gene delivery systems can be improved and optimized for the required needs; 
however their activity is cell-specific and a generalization for other tissues 
may not be possible. Unfortunately, there does not seem to be such thing as a 
“one fits all” delivery system. In conclusion, ex vivo gene therapy to the RPE 
may be a successful approach, especially if combined with RPE tissue 
engineering; the genetically modified and reconstructed RPE monolayer may 
replace the tissue in vivo, support the neural retina with neurotrophic 
factors, and also secrete antiangiogenic proteins to prevent 
neovascularization. 
The reconstruction of the RPE is a valid therapeutic option in the case of 
advanced AMD patients, where scarring and tissue atrophy have already 
occurred. It is worthwhile remembering that 95% of all AMD patients have 
currently no cure available to treat the disease and prevent vision loss. 
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Several attempts have been made to replace the diseased RPE with functional 
RPE (Schraermeyer et al., 2001, Lu et al., 2009, Idelson et al., 2009, Lund et 
al., 2006), however in these studies the replacement cells were injected 
subretinally as a suspension and without any support, which would promote 
the correct cellular arrangement and protect the transplanted cells from the 
hostile environment found in AMD eyes 
In our study we used human embryonic stem cell-derived RPE (hESC-
RPE) as cell source and the synthetic non-biodegradable polymer polyimide 
as RPE carrier substrate. The safety and tolerability of hESC-RPE cell 
therapy in humans has been recently assessed in a clinical trial (Schwartz et 
al., 2012), while polyimide is already clinically approved for ocular use and 
its biocompatibility has been demonstrated in several ophthalmic 
applications (Kane et al., 2008, Besch et al., 2008, Julien et al., 2011). The 
cells adopted RPE like phenotype with intense pigmentation, expressed 
melanogenesis-related genes microphthalmia-associated transcription factor 
(MITF), pre-melanosome protein 17 (PMEL), and tyrosinase (TYR), and 
RPE-specific genes retinal pigment epithelium-specific 65 kDa protein 
(RPE65), bestrophin-1 (BEST), pigment epithelium-derived factor (PEDF), 
and cellular retinaldehyde-binding protein (CRALBP). Furthermore, the 
monolayers exhibited polarity with apical expression of Na/K-ATPase and C-
mer proto-oncogene tyrosine kinase (MERTK), expressed the tight junction 
protein 1 (ZO-1), and phagocytosed shed outer segments. The RPE 
monolayers exhibited a barrier function which was moderately leakier than 
the normal RPE tissue. One drawback of hESC-RPE monolayers grown on 
polyimide membrane is the very long differentiation and maturation time 
(several months) required to achieve a functional RPE; shortening of the 
protocols used to engineer the RPE monolayers would make them more 
appealing from a therapeutic point of view, as well as for their use as RPE cell 
models for in vitro drug screening. 
The transplantation of a tissue engineered RPE monolayer is expected to 
be beneficial when the photoreceptors are still intact; in this case the 
transplanted RPE may prevent photoreceptor cell loss and preserve the 
viability and function of the neural retina. If, however, photoreceptor cell 
death has already occurred, replacement of the RPE alone may not be 
sufficient. In this case, in addition to the RPE, also the photoreceptor cell 
layer must be reconstructed. In both cases such treatments are likely to be 
very costly and, considering the large number of potential patients, their 
future implementation in the current standards of care for AMD may be 
economically unsustainable. 
The treatment of neovascularization in wet AMD has improved 
enormously since the introduction of anti-neovascular agents; however the 
much more common dry AMD remains still untreatable. Recently, the 
chronic exposure to oxidative stress and a decline in lysosomal activity of 
RPE cells have been recognized as a possible cause for RPE atrophy in dry 
AMD (Winkler et al., 1999, Kaarniranta et al., 2013, Jarrett and Boulton, 
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2012). Dry AMD is characterized by protein misfolding, accumulation of 
protein aggregates inside and underneath the RPE, and abnormal protein 
degradation that eventually lead to the degeneration of the RPE. Heat shock 
proteins (Hsps) are responsible for the correct folding of proteins and 
members of the Hsp70 family have the remarkable ability to dissolve protein 
aggregates; therefore Hsp70 protein therapy may protect RPE cells from 
oxidative stress and degeneration. Our study showed that Hsp70 therapy 
protects RPE cells from oxidative harm, and that the protein can be delivered 
to the RPE in vitro and also after intravitreal administration in an isolated 
porcine eye. Clearly this type of protein therapy needs to be started early in 
AMD patients, when the RPE cell layer is not yet compromised. Nevertheless, 
this work may hopefully provide a novel therapeutic option for the treatment 
of RPE degeneration in AMD. 
The approaches mentioned so far for the treatment of AMD are suffering 
from one major flaw: they are invasive and in some cases they require 
repeated administrations. The subretinal transplantation of a tissue 
engineered and genetically modified RPE monolayer is a difficult technique 
that requires surgery and dedicated medical personnel with special skills. 
Intravitreal injections are easier to perform and currently carried out in an 
ambulatory setting, however the discomfort for the patient is not to be 
undervalued, especially considering that these injections are given monthly 
or even more often. Therefore, delivery systems that can efficiently target the 
diseased ocular tissues, generate therapeutic drug levels, and maintain 
prolonged and effective concentrations are highly desirable. The major 
hurdle in designing such delivery systems is to ensure that the structure and 
activity of biologics are retained during the preparation, sterilization and 
release processes (El Sanharawi et al., 2010). 
Ocular drug delivery systems fall into five categories: implants, 
microspheres, nanoparticulates, cell encapsulation (ECT) (discussed 
previously), and hydrogels (del Amo and Urtti, 2008). Implants, which can 
be biodegradable or non-biodegradable, are positioned intravitreally with a 
minor surgery and are designed to release the encapsulated drugs for a 
prolonged period of time. Since 1996, four implants have been approved for 
the delivery of small molecule drugs to the back of the eye, Vitrasert 
(withdrawn from the market in 2013), Retisert, Ozurdex, and Iluvien. 
Recently, pSivida, the company involved in the development of three of the 
commercially available implants, has designed a delivery system (Tethadur) 
for the sustained delivery of bevacizumab. The implant, made of nanoporous 
silicon, controls the release of the antibody through its pore size. 
Sustained drug release can also be obtained when the drug is 
encapsulated into microspheres (1-1000 µm). Biodegradable microspheres 
composed of biocompatible and FDA approved polymers poly (lactic acid) 
(PLA), poly (glycolic acid) (PGA) and their copolymers poly (lactic-co-
glycolic acid) (PLGA) are the most employed. These polymers have different 
degradation rates (PLGA>PLA and PGA), therefore, by varying the ratio and 
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the molecular weight of the polymers used in the formulation, the 
degradation rate of the microspheres can be controlled. After intravitreal 
injection, these microspheres tend to aggregate and sink to the lower part of 
the vitreal cavity (Giordano et al., 1995, Herrero-Vanrell and Refojo, 2001, 
Cardillo et al., 2006, Barcia et al., 2009), therefore the risk of vitreal clouding 
is reduced. PLGA microspheres have been used in animal models to deliver 
biologics to the back of the eye. Intravitreally administered PLGA 
microspheres delivering glial cell line-derived neurotrophic factor (GDNF) 
protected retinal ganglion cells in a rat model of glaucoma (Jiang et al., 2007, 
Checa-Casalengua et al., 2011) and promoted photoreceptor survival in a 
retinal degeneration mouse (Andrieu-Soler et al., 2005). PLGA microspheres 
were also used to deliver an anti-VEGF RNA aptamer through a rabbit sclera 
ex vivo, the transcleral diffusion of the aptamer was followed for 6 days 
(Carrasquillo et al., 2003). Furthermore PLGA microspheres loaded with PEI 
complexed to antisense TGF-B2 oligonucleotides and administered by 
subconjunctival injection in rabbits, increased the intracellular penetration 
of the oligonucleotides in conjunctival cells and were able to prevent post-
surgical fibrosis after glaucoma filtering surgery (Gomes dos Santos et al., 
2006). One potential drawback of PLGA polymers is caused by their 
degradation into lactic and glycolic acid; these acidic molecules lead to a pH 
drop in the core of the microspheres that can compromise the stability of the 
encapsulated biologics (van de Weert et al., 2000, Zhu et al., 2000). 
Nanoparticulates (1-1000 nm), such as polymeric nanoparticles, micelles, 
and liposomes, are self-assembling systems that have been extensively 
studied for the delivery of genetic material in vitro and in vivo. As discussed 
earlier, cationic nanoparticles may aggregate and be stuck in the negatively 
charged vitreous; however negatively charged PLA nanoparticles loaded with 
fluorophores were shown to diffuse rapidly in the vitreous, penetrate the 
retina and localize in the RPE for 4 months after a single intravitreal 
injection (Bourges et al., 2003). Furthermore PEDF peptides protected the 
rat retina from ischemic injury when delivered in PLGA nanospheres (Li et 
al., 2006). Sakai and colleagues (Sakai et al., 2007) evaluated the 
neuroprotective effect of bFGF-containing nanoparticles in RCS rats; the 
nanoparticles were present in several retinal layers and the RPE until 8 
weeks after intravitreal administration and prevented photoreceptor 
degeneration. Liposomes have been shown to improve the intraocular 
pharmacokinetic properties of biologics. For example, the mean 
concentration of bevacizumab after intravitreal injection was twice higher at 
day 28 and 5 times higher at day 42, compared to free bevacizumab, if the 
antibody was encapsulated inside liposomes (Abrishami et al., 2009). The 
intravitreal concentration of a model 16-mer oligonucleotide was 9.3-fold 
higher when it was delivered inside liposomes compared to free 
oligonucleotide (Bochot et al., 2002), and also, 24 h after administration, the 
intravitreal amount of a vasoactive intestinal peptide encapsulated inside 
liposomes was 15 times greater than after injection of the peptide in saline 
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(Lajavardi et al., 2007). Another advantage of liposomes is that the 
encapsulated drugs appear to be less toxic, because only a limited amount of 
drug comes in direct contact with the ocular tissues (Short, 2008). 
Hydrogels are made from polymers that upon a stimulus, such as 
temperature, pH, or ion concentration, undergo a phase change. These 
materials are liquid and can be delivered with a syringe, but once inside the 
eye they form a semi-solid matrix that retains the drug and releases it over 
time. Gel forming solutions are already in clinical use for the topical delivery 
of small molecule drugs (Timoptic-XE – timolol maleate, Pilogel – 
pilocarpine, and AzaSite – azithromycin) (del Amo and Urtti, 2008), 
however intravitreal gelifying systems for the controlled delivery of biologics 
still need further investigation. 
Overall, the use of biological therapies to treat human disease is growing 
rapidly and millions of patients suffering from eye disorders, cancer, 
infectious diseases, inflammatory diseases, autoimmune disorders, 
cardiovascular diseases, blood disorders, and diabetes are successfully 
treated with biologics. Paradoxically, the success of biological therapies is 
starting to be a growing problem for public healthcare services worldwide, 
indeed, while these new therapies offer hope for the treatment of previously 
incurable diseases, they also tend to be much more expensive than 
conventional drugs, and managing their use is a challenge for payers (Kelly 
and Mir, 2009). One extreme case is Glybera, an AAV-based gene therapy for 
the rare genetic disease lipoprotein lipase deficiency that costs over € 1 
million per patient. Healthcare costs are on an unsustainable trajectory in 
most developed countries, and this trend is expected to continue in the 
coming years with an aging population, and the growing incidence of lifestyle 
diseases. Therefore, the management of healthcare costs without having to 
compromise the access to quality medical care remains one of the most 
daunting challenges that governments are faced with. Many factors 
contribute to the high cost of biologics, including the complex manufacturing 
processes, and the fact that no other treatment may be available for a certain 
medical condition. Furthermore, most biologics cannot be taken by the 
patient directly, but instead, they have to be administered parenterally in a 
hospital thereby also contributing to the overall expenditure. 
Given that the first biologics were approved in the 1980s, however, the 
exclusive rights, including patents and other data protection, for several 
biological medicinal products have reached their expiration. Consistent with 
this expiry, generic biological medicinal products, or biosimilars as they are 
commonly called, are being developed and several are already available on 
European markets, with the first approved and marketed in 2006. As their 
name implies, biosimilars, unlike generic drugs where the active ingredients 
are identical, are similar but not identical copies of the original biologic. 
Indeed, the inherent complexity of biologics precludes identical copies; 
similar to snowflakes, biosimilars from different manufacturers will differ 
from the original biologic and from each other. Nevertheless, according to 
Discussion 
84 
the EMA a biosimilar and the original biologic are expected to have the same 
safety and efficacy profile. Biosimilars may offer a less-costly alternative to 
existing biologics; as a result, their increased availability may improve access 
to biological medicines for more patients and contribute to the financial 
sustainability of healthcare systems. Thus, the development of biosimilars 
offers potential economic benefit to healthcare systems while addressing the 
issue of new treatment options brought about by advances in medical 
science.
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11 CONCLUSIONS 
In this thesis, the delivery of various biologics, including DNA, cells, peptides 
and proteins to the retinal pigment epithelium was explored. In response to 
the aims at page 28, the conclusions of this study are as following: 
 
1. A standardized transfection protocol was developed and systematically 
optimized to obtain reproducible, high-level gene transfer to retinal 
pigment epithelial cells (ARPE-19) in vitro, using branched 
polyethylenimine (PEI) as a gene carrier. The development of the 
protocol involved the optimization of several parameters such as cell 
density at seeding, PEI/DNA charge ratio, composition of the 
preparation buffer and nanoparticulate assembly conditions as well as 
incubation time of the nanoparticulates with ARPE-19 cells. The 
selection of the most effective conditions for gene transfer led to the 
finalization of the present protocol that provides a relatively simple 
and reproducible procedure for the pre-selection of potential 
candidate reagents as non-viral gene delivery systems to the RPE. 
 
2. The transfection protocol developed in point 1 was used to transfect 
ARPE-19 cells, human primary RPE, and hESC-RPE cells. 
Transfection efficacy and duration increased when optimized genetic 
materials including episomal EBNA-1 plasmid, human promoter, and 
minicircles were used. Several carriers including lipoplexes and 
amphiphilic block copolymer core-shell micelles showed promising 
results compared to branched PEI. 
 
3. In our work we explored the functionality of Tat peptide, one of the 
most widely studied CPPs. Our results indicated that it is not the 
sequence of Tat per se that dictates cell uptake, but the cationic charge 
of the peptide. These cationic peptides seem to act via ionic 
interactions that should be operative regardless of the sequence and 
trigger peptide endocytosis Moreover no direct penetration was 
observed; instead the peptides were endocytosed and, as it is often the 
case in non-viral gene delivery, ended their journey inside lysosomes. 
Cell-surface glycosaminoglycans inhibited Tat peptide internalization. 
Based on our results we think that Tat peptide may not hold promise 
for the delivery of biologics to the RPE due to the unspecific mode of 
action and inability to escape from the endosomal compartments. 
 
4. Ocular stem cell therapy holds promise for the reconstruction of the 
degenerated RPE monolayer in AMD patients; in addition, engineered 
human RPE constructs may also provide a unique platform for drug 
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discovery and toxicology. We have grown a functional RPE tissue in 
vitro by using human embryonic stem cells as cell source and the 
synthetic polymer polyimide as supporting scaffold for the growth and 
maturation of the cells. Human embryonic stem cell-derived RPE 
successfully matured on polyimide biomembranes and acquired RPE-
like properties, including characteristic RPE phenotype, expression of 
RPE markers, barrier and phagocytic function. 
 
5. RPE degeneration in dry AMD is caused by the aggregation of proteins 
inside RPE cells, and is currently untreatable. We investigated the 
cytoprotective properties of heat shock protein 70 kDa (Hsp70) 
against oxidative damage and the feasibility of rhHsp70 protein 
therapy as a potential therapeutic approach for dry AMD. Heat shock 
protein 70 kDa therapy protected the RPE from oxidative stress. The 
exogenously delivered protein was internalized into RPE cells, 
localized inside late endosomes and lysosomes, and was found to 
diffuse to the outer ocular layers, including the RPE, after intravitreal 
administration in ex vivo eyes. These results may hopefully provide a 
valid therapeutic strategy for the treatment of RPE degeneration, 
which is at the basis for the development of AMD. 
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